baber/WOPTO huggingface dataset:
Patent NZ-236552-A (NZ)
Title: Arcuate shaped belt for securing absorbent pad
Inventor: NEW NANCY ANN
IPC: A61F13/15
Filed: 1990-12-19
Abstract: Disclosed is a disposable absorbent garment (10, 10", 10'") having a belt (12, 12', 12", 12'"). The belt may either be integral with (12", 12'") or detachable (12, 12') from the absorbent portion of the garment. The belt (12, 12") is arcuate so that one laterally extending edge (16, 16") of the belt is longer than the other laterally extending edge (16, 16") of the belt. This arrangement provides a better fitting belt which more discretely conforms to the contours of the wearer and is less noticeable under clothing. Alternatively, the belt (12'") may have a portion which is worn relatively high on the wearer's back, portions which extend diagonally downward to the front of the wearer and a portion which is worn relatively low, below the stomach of the wearer in front. This arrangement provides a belt (12'") which generally does not interfere with the portions of the wearer's body which encounter large ranges of motion during normal movements of the body.
Patent NZ-277479-A (NZ)
Title: Determination of water in milk using ir attenuation and freezing point depression
Inventor: ARNVIDARSON BORKUR
IPC: G01N21/3577
Filed: 1994-12-09
Abstract: PCT No. PCT/DK94/00462 Sec. 371 Date Jun. 10, 1996 Sec. 102(e) Date Jun. 10, 1996 PCT Filed Dec. 9, 1994 PCT Pub. No. WO95/16201 PCT Pub. Date Jun. 15, 1995The present invention relates to a method for quantitatively assessing the amount of any extraneous water contained in a milk sample, the method comprising the steps of (a) performing a determination of the infrared (IR) attenuation of the sample in at least one waveband, (b) quantitatively assessing the amount of any extraneous water in the sample on the basis of the determination (a) and predetermined regression coefficients derived from multivariate calibration with respect to the relationship between infrared attenuation in the at least one waveband and the amount of extraneous water. The invention furthermore relates to a similar method for determining the freezing point depression of the sample. In addition, the invention relates to a method for the establishment of a set of regression coefficients for use in an instrument which determines the amount of extraneous water or the freezing point depression of a milk sample.
Patent NZ-292417-A (NZ)
Title: 7h-1,3-dioxolo[4,5-h] [2,3]-benzodiazepine derivatives and medicaments
Inventor: ANDERSON BENJAMIN ALAN
IPC: C07D491/056
Filed: 1995-08-30
Abstract: Compounds having general formula (I) wherein R is hydrogen or C 1  - C 10  alkyl; X is an aromatic moiety selected from phenyl, thienyl, furyl, pyridyl, imidazolyl, benzimidazolyl, benzothiazolyl and phthalazinyl which is unsubstituted or substituted with one or more moieties chosen from the group consisting of halogen, hydroxy, cyano, nitro, C 1  - C 6  alkyl, C 3  - C 6  cycloalkyl, C 1  - C 4  alkoxy, carboxy, C 1  - C 6  alkoxycarbonyl, acetyl, formyl, carboxymethyl, hydroxymethyl, amino, aminomethyl, methylenedioxy and trifluoromethyl; and "Aryl" represents p-nitrophenyl, p-aminophenyl or p-(protected amino) phenyl; or a pharmaceutically acceptable salt thereof, are useful as anticonvulsants.
Patent NZ-293907-A (NZ)
Title: Fluid treatment in a closed system comprising a housing and at least one radiation source
Inventor: MAARSCHALKERWEERD JAN M
IPC: A61L2/10
Filed: 1995-10-16
Abstract: A fluid treatment device comprising a housing for receiving a flow of fluid, the housing comprising a fluid inlet, a fluid outlet, a fluid treatment zone disposed between the fluid inlet and the fluid outlet, and at least one radiation source module disposed in the fluid treatment zone, the at least one radiation source module comprising a radiation source sealably connected to a leg, the leg sealably mounted to the housing, the radiation source being disposed substantially parallel to the flow of fluid. A method of treating a fluid in a housing comprising a fluid inlet, a fluid outlet, a fluid treatment zone disposed between the fluid inlet and the fluid outlet, the fluid treatment zone having at least one radiation source disposed therein is also described. The method comprises the steps of: (i) providing a flow of the fluid to the fluid inlet; (ii) feeding the flow of fluid from the fluid inlet to the fluid treatment zone in a manner substantially parallel to the at least one radiation source; (iii) irradiating the flow of fluid in the fluid treatment zone; and (iv) feeding the flow of fluid to the fluid outlet. During the method, the flow of fluid through the fluid inlet, the fluid outlet and the fluid treatment zone is substantially collinear. The fluid treatment device and method are ideally suited (but not limited) to inactivate microorganisms present in water.
Patent NZ-312285-A (NZ)
Title: TNF-alpha converting enzyme (TACE)
Inventor: BLACK ROY ALVIN
IPC: A61P15/00
Filed: 1996-06-03
Abstract: Described is a metalloprotease TNF-alpha converting enzyme (TACE) that converts TNF-alpha from the 26kD cell form to the cell form to the 17 kD form. This enzyme has been isolated and purified and the cDNA sequenced. The protease has a molecular weight of approximately 80 kD. Assays for detecting the protease-inhibiting activity of a molecule are also described.
Patent NZ-329174-A (NZ)
Title: Use of a tetrahydronaphthalene or tetrahydroisoquinoline derivative for treating atherosclerosis
Inventor: AIELLO ROBERT JOSEPH
IPC: A61K31/445
Filed: 1997-11-13
Abstract: A tetrahydronaphthalene or tetrahydroisoquinoline derivative of formula I, an optical or geometric isomer, a pharmacologically acceptable acid addition salt, N-oxide, ester or quaternary ammonium salt thereof is used in the manufacture of a medicament for treating atherosclerosis which is independent of lipid lowering.  In formula I: A is CH2 and NR; B, D and E are independently CH or N; Y is optionally substituted phenyl, naphthyl, cycloalkyl, cycloalkenyl, a five membered heterocycle containing up to two heteroatoms selected from -O-, -NR2 and -S(O)n, a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, NR2 and -S(O)n or a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring and containing up to two heteroatoms selected from the group consisting of -O-, -NR2 and -S(O)n; Z1 is -(CH2)pW(CH2)q-, -O(CH2)p CR5R6-, -O(CH2)pW(CH2)q, -OCHR2CHR3- or -SCHR2CHR3-; G is a group: a) 	-NR7R8; b)	an optionally substituted group of formula II which can be optionally fused on adjacent carbon atoms with one or two phenyl rings wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S- or -CH2- or c)	optionally substituted a bicyclic amine containing five to twelve carbon atoms, either bridged or fused or Z1 and G together form a group of formula III W is  -CH2-, -CH=CH-, -O-, -NR2-, -S(O)n-, -CO-, -CR2(OH)-, -CONR2-, -NR2CO-, a group of formula IV or -C=C-; R is hydrogen or alkyl; R2 and R3 are independently hydrogen or alkyl; R5 and R6 are independently alkyl or together form a carbocyclic ring; R7 and R8 are independently optionally substituted phenyl, optionally saturated carbocyclic ring, a heterocyclic ring containing up to two heteroatoms selected from -O-, -N- and -S-, H, alkyl or form a 3 to 8 membered nitrogen containing ring with R5 or R6 or a ring formed by R7 and R8 may be optionally fused to a phenyl ring; e is 0, 1 or 2; p is 0,1,2 or 3 and q is 0,1,2 or 3.
Patent NZ-336235-A (NZ)
Title: Compounds containing 1,4-benzodioxane ring as antiobesity agents with antidiabetic, antihyperglycemic and antiobesity properties
Inventor: VENKATESAN ARANAPAKAM MUDUMBAI
IPC: A61K31/357
Filed: 1997-12-18
Abstract: Substituted 1,4-benzodioxane compounds having antidiabetic, antihyperglycemic, and antiobesity properties represented by formula (II) and pharmaceutically acceptable salts thereof, a salt thereof; an enantiomer thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof.  Wherein;  R1 and R6 are independently hydrogen, C1-6 alkyl, trifluoromethyl, cyano, C1-6alkoxy, or halogen;  R2 is hydrogen or C1-6trialkylsilyl;  R3 is hydrogen or C1-6alkoxycarbonyl; or  R2 and R3 are joined to form the oxazolidinone ring (III);  R4 and R5 are independently hydrogen or C1-6 alkyl;  R7 and R8 are independently OR9 or NR10R11;  R9 is hydrogen, C1-12alkyl, C1-12cycloalkyl, C1-12silylalkyl, phenyl, naphthyl, phenyl C1-6alkyl, C1-6alkoxy C1-6alkyl, pyridyl, thiophenyl, furanyl, imidazolyl, oxazolyl, -CHR12COOR13, -CHR12C(O)R13, -CHR12CONR10R11, -CHR12OCOOR13, or -CHR12OC(O)R13;  R10 and R11 are independently hydrogen, C1-12alkyl, phenyl, naphthyl, phenyl-C1-6alkyl, furanylalkyl, or alkoxycarbonylalkyl;  R12 and R13 are independently hydrogen, C1-12alkyl, phenyl, naphthyl, or phenyl-C1-6alkyl;
Patent NZ-337517-A (NZ)
Title: Portable resilient laminated insulating panel with stiffening ribs
Inventor: THOMPSON PATRICK ANDREW
IPC: F25D23/08
Filed: 1999-08-30
Abstract: A portable reinforced insulation panel 30, 32, 34, 50 is disclosed. The panel is formed as layer(s) of insulating material with the penultimate layer being a stiffening reinforcing layer 52 covered with an insulation layer (not shown). Additional stiffening members 56, 58 are longitudinal ribs perpendicular to reinforcing layer 52.
Patent NZ-501785-A (NZ)
Title: 4-(3,4-dihydro-2-naphthylmethyl)- or 4-(2H-3-chromenylmethyl)-4,5-dihydro-1H-imidazole derivatives
Inventor: CORDI ALEX
IPC: C07D233/10
Filed: 1999-12-14
Abstract: The imidazoline derivatives have the formula (I) or tautomers, enantiomers, diastereoisomers and pharmaceutically acceptable addition salts thereof wherein: A is an optionally substituted benzene ring; B is imidazoline ring of formula (Ia) or (Ib); X represents CR6 or CR6R7, nitrogen, NR8, oxygen, sulphur or SO or SO2; Y is CH, CH2 or a single bond provided that when Y is a single bond then ring containing X, Y and Z has the formula (1c); Z is carbon or CR4; R1, R2 and R3 are independently hydrogen or alkyl or R2 and R4 or R1 and R4 can form cyclopropane; R4 is hydrogen or alkyl; R5 is hydrogen, alkyl or benzyl; R6 and R7 are independently hydrogen or alkyl; R8 is hydrogen, alkyl or benzyl and the symbol --- means that the bonds can be single or double so long as the valency of the atoms is respected. A pharmaceutical composition thereof is useful for treating depression, obesity, panic attacks, anxiety, obsessive-compulsive disorders, cognitive disorders, phobias or Parkinson's disease.
Patent NZ-502496-A (NZ)
Title: Pneumatic product vending system and loader for adapting existing vending machines
Inventor: BUSTOS RAFAEL T
IPC: G07F11/46
Filed: 1998-07-08
Abstract: An existing product vending machine (24) is adapted with an interface unit (30) to serve as a storage and loading device for use in a remote pneumatic product vending and dispensing system. The interface unit (30) replaces the front panel of the existing product vending machine (24). The interface unit (30) comprises a panel, shaped to cover the access opening and connect with the supporting and latching structure (28, 38, 39, 40) of the existing vending machine (24), a loading tube (44) to couple to the tube (26) of the pneumatic conveying system, a loading device (50) to direct the selected product into the loading port of the loading tube (44), control lines connected to the control circuitry of the existing vending machine and the controller of the pneumatic product vending and dispensing system and an air pump or blower (41) to move the selected product through the loading tube (44) to the tube (26) of the pneumatic conveying system.
Patent NZ-505348-A (NZ)
Title: 11beta-halogen-7alpha-substituted estratriene derivatives
Inventor: BOHLMANN ROLF
IPC: C07J43/00
Filed: 1998-12-23
Abstract: An 11-b-halogen-7-a-substituted estratrienes derivative has the formula (I) wherein: R3 is H, hydrocarbon or R3'-C(O); R3' is H, hydrocarbon or phenyl; R7 is A-B-Z-R20; A is a direct bond, or benzylidene radical whereby the methylene group is bonded to the 7th carbon atom of the steroid or a phenylene radical; B is an alkylene, alkenylene or alkynylene; Z is -NR21- with R21 being alkyl and R20 being H, alkyl, alkenyl, alkynyl, -D-CnF2n+1, -L-CH=CF-CpF2p+1, -D-O-(CH2)r-CnF2n+1 or -D-O-(CH2)q-aryl or NR20R21 can form an optionally saturated optionally substituted heterocycle optionally containing one or two additional heteroatoms of nitrogen, oxygen or sulphur or Z is -SOx with x being 0 to 2 and R20 being alkyl, alkenyl, alkynyl, -D-CnF2n+1, -L-CH=CF-CpF2p+1, -D-O-(CH2)r-CnF2n+1 or -D-O-(CH2)q-aryl or Z is -NR31- with R31 being -C(O)R33 or -CH2-R33 and R20 being alkyl, alkenyl, alkynyl which can be partially fluorinated or interrupted by up to 3 heteroatoms of O, S or NR32 or R20 is optionally substituted cycloalkyl, cycloalkylalkyl, aralkyl, heteroarylalkyl, aminoalkyl, aryl or heteroaryl limited by the exclusions listed in the specification; R11 is F or Cl, R17 is H or -C(O)-R17' and R17', R32 and R33 are as defined in the specification; The compounds described above have anti-estrogen or tissue selective estrogenic activity.
Patent NZ-515353-A (NZ)
Title: Cyclothiocarbamate derivatives as progesterone receptor modulators
Inventor: ZHANG PUWEN
IPC: A61P15/18
Filed: 2000-05-01
Abstract: A compound of formula (I) used for the treatment of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon or prostate; dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, fibroids, or post menopausal hormone replacement therapy, and as a contraceptive.
Patent NZ-526864-A (NZ)
Title: Method of predicting oestrus or delivery date or diagnosis of a disease of an animal by using a vibrograph to measure the movement of the animal
Inventor: SASAGURI KOUJI
IPC: A61B5/11
Filed: 2003-07-04
Abstract: A method of predicting the estrus and the delivery date of a cow, swine, or horse and discovering diseases by analysis of frequency values, comprises: attaching an attachable frequency measuring device to a leg portion, a neck portion, or a chin portion of a cow, swine or horse; accurately measuring frequency values inclusive of fine vibration frequency values by the vibration measuring part of the attachable frequency measuring device; constantly wirelessly transmitting the frequency value information from the vibration measuring part of the attachable frequency measuring device to a remote centralized computer by a transmission function, inputting the transmitted frequency value information to the centralized computer, and storing the transmitted frequency value information in a storage function; representing the frequency value information stored in the storage function in the form of a graph in units of hours by a graphics function included in the centralized computer; analyzing the time of estrus, the date of delivery and the symptom of a disease of the cow, swine, or horse with the graph by means of an analysis function and using the information obtained using the analysis function to predict the time of estrus of the cow, swine, or horse by an estrus predicting function included in the centralized computer, and predicting the date of delivery after insemination of the cow, swine, or horse by a delivery date predicting function included in the centralized computer, and further, discovering a disease of the cow, swine, or horse by a disease discovering function included in the centralized computer. The frequency values includes an intermittent-vibration frequency value generated by the excitement of the cow, swine, or horse during estrus, a continuous-vibration frequency value based on walking or exercise, and a static- vibration or non-vibration frequency value indicative of a static-vibration or non-vibration state such as sleeping. The graph can be a bar graph or a line graph.
Patent NZ-527144-A (NZ)
Title: 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
Inventor: DELCANALE MAURIZIO
IPC: A61P5/32
Filed: 2002-01-21
Abstract: 2-H-1-Benzopyran derivatives of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed is the use of such a compound for the preparation of a medicament useful in the prevention and treatment of a number of postmenopausal pathologies, in particular osteoporosis, coronary heart disease and estrogen dependent human cancer.
Patent NZ-527397-A (NZ)
Title: Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
Inventor: VILLALOBOS ANABELLA
IPC: A61K31/56
Filed: 2002-02-20
Abstract: A pharmaceutical composition comprising of a GABAA inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier and for the treatment of diseases of cognitive dysfunction in a mammal is disclosed. The GABAA inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment associated with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS associated dementia and attention deficit disorder.
Patent NZ-529789-A (NZ)
Title: Manufacture of polyglutamate-20(S)-camptothecin conjugates
Inventor: KUMAR ANIL M
IPC: A61K47/48
Filed: 2000-10-12
Abstract: A process for preparing a polyglutamic acid-20(S)-campotothecin conjugate and the conjugate produced is disclosed. A pharmaceutical composition for the treatment of cancer comprising an effective amount of the polyglutamic acid-camptothecin conjugate is also disclosed. (62) Divided out of 518262
Patent NZ-531345-A (NZ)
Title: Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
Inventor: GITTOS MAURICE WARD
IPC: A61P25/28
Filed: 2002-08-22
Abstract: Bisulphate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress- related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred bisulphate salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate and, especially, 3(3- methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate.
Patent NZ-531467-A (NZ)
Title: Reduction of metal oxides in an electrolytic cell operating above the threshold potential
Inventor: STREZOV LES
IPC: C25C3/18
Filed: 2003-03-13
Abstract: A method of reducing a metal oxide, such as titania in a solid state in an electrolytic cell is disclosed. The electrolytic cell includes an anode, a cathode, and a molten electrolyte. The electrolyte includes cations of a metal that is capable of chemically reducing the metal oxide. The metal oxide in a solid state is immersed in the electrolyte. The method includes a step of operating the cell at a potential that is above a potential at which cations of the metal that is capable of chemically reducing the metal oxide deposit as the metal on the cathode, whereby the metal chemically reduces the metal oxide.
Patent NZ-533348-A (NZ)
Title: Method of supporting the viability, proliferation and/or differentiation of mammalian dendritic cells comprising culturing dendritic cells and/or precursors thereof in the presence of mononuclear immune cells
Inventor: HART DEREK NIGEL JOHN
IPC: C12N5/02
Filed: 2002-11-26
Abstract: A method of supporting the viability, proliferation and/or differentiation of mammalian dendritic cells wherein the method comprises culturing dendritic cells and/or precursors thereof in the presence of an effective number of mononuclear immune cells. Furthermore the culture is not supplemented with exogenous cytokine and the method is carried out for a time and under conditions sufficient of the mononuclear immune cells to support the dendritic cells and/or precursors thereof.
Patent NZ-538121-A (NZ)
Title: Method and system for GSM billing during WLAN roaming
Inventor: KAUZ MICHAEL
IPC: H04L12/56
Filed: 2002-10-08
Abstract: A method and system for recording and billing services during the roaming of a mobile IP node in heterogeneous WLANs. First call detail records are transmitted from an access server to a billing module and second call details are transmitted from the access server to a proxy module. The service requested from a provider of a fixed network is billed by means of a clearing module and/or the TAP files are transmitted to a GSM service provider for billing.
Patent NZ-538474-A (NZ)
Title: Golf club device
Inventor: KARLSEN JON
IPC: A63B53/04
Filed: 2003-08-15
Abstract: A golf club device, more specially a putter (1), comprising a head (2) and a shaft (3) attached to the head (2), possibly being provided with a grip, wherein the moment of mass inertia of the head (2) constitutes less than seventy-nine per cent of the total moment of inertia of the putter (1) when the putter (1) is rotated about an axis of rotation (4), which is perpendicular to the longitudinal axis (7) of the shaft (3) and about one hundred and twenty centimeters from the longitudinal axis (5) of the head (2), and/or wherein the mass of the shaft, including a possible displaceable weight (11), divided by the length of the shaft is at lest one hundred and seventy grams per meter of shaft in a shaft which is up to one meter long, and at least one hundred and ninety grams per meter of shaft in a shaft which is longer than one meter.
Patent NZ-540699-A (NZ)
Title: Amino acid derived prodrugs of propofol, compositions and uses thereof
Inventor: GALLOP MARK A
IPC: C07C329/06
Filed: 2004-01-28
Abstract: Disclosed are compounds of formula (I) wherein: X is selected from the group consisting of a bond, CH2, NR11, O and S; m is 1 or 2; n is ) or 1; R1 is selected from the group consisting of H, [R5NH(CHR4)pC(O)]-. R6-, R6C(O)- and R6OC(O)-; R2 is OR7 or -[NR8(CHR9)qC(O)OR7]; R3 is selected from the group consisting of H, alkyl, substituted alkyl, alkoxycarbonyl, aryl, substituted aryl, arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, heteroaryl, substituted heteroaryl and heteroarylalkyl; and the remaining substituents are as defined in the specification. The compounds disclosed are prodrugs of propofol useful for the treatment or preventions of migraines, nausea, vomiting, anxiety, seizure, convulsions, trauma of the central nervous system, and neurodegenerative conditions.
Patent NZ-542964-A (NZ)
Title: Stable, highly concentrated liquid formulations, which are particularly suitable for subcutaneous administration
Inventor: LIU JUN
IPC: A61K47/26
Filed: 2004-03-29
Abstract: Disclosed are highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The formulations comprise arginine-HC1, histidine and polysorbate.